Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 2/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 8/20 | 0.41 |
| ▸ | CDK1 | P06493 | 7/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.41 |
| ▸ | MGMT | P16455 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542009 | 0.77 | PDPK1 (0.59) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL28731074 | 0.77 | PDPK1 (0.59) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL28004538 | 0.76 | PDPK1 (0.54) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL669639 | 0.75 | — | — | |
| SCHEMBL5509118 | 0.74 | PDPK1 (0.56) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL29721618 | 0.74 | PDPK1 (0.56) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL7753244 | 0.73 | PDPK1 (0.59) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL29380739 | 0.73 | PDPK1 (0.59) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL9702644 | 0.73 | PDPK1 (0.50) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL7165321 | 0.72 | PDPK1 (0.53) | PDPK1GDAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | MODERNATX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4387596-A1 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387597-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| US-12005074-B2 | Extrahepatic delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| WO-2015034928-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150071889-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-03-12 | — | — | US | disclosed |
| WO-2015006498-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014165825-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140227293-A1 | METHOD FOR CONTROLLING TUMOR GROWTH, ANGIOGENESIS AND METASTASIS USING IMMUNOGLOBULIN CONTAINING AND PROLINE RICH RECEPTOR-1 (IGPR-1) | TRUSTEES OF BOSTON UNIVERSITY (US) | 2014-08-14 | — | — | US | disclosed |
| US-8802438-B2 | Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140154783-A1 | BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20120316220-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120046346-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110135632-A1 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | NSUN3, IGLV6-57, MRPS23 | PDPK1 4318/4885GDA 3747/4885PI4KA 1891/4885 |
| US-20120316220-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | MTREX, STING1, AGO2 | PDPK1 2443/4885GDA 1003/4885PI4KA 1736/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | PDPK1 3676/4885GDA 891/4885PI4KA 3158/4885 |
| US-12005074-B2 | Extrahepatic delivery | RNASE1, SLC10A1, FABP1 | PDPK1 4372/4885GDA 936/4885PI4KA 3862/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | PDPK1 1701/4885GDA 799/4885PI4KA 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.